MOLOGEN AG RAISES FUNDS FOR CLINICAL TRIALS BY INCREASING SHARE CAPITAL
Through an increase in capital share, MOLOGEN AG (ISIN DE0006637200) has raised funds for further clinical studies. A total of 683,800 shares were placed with Absolute Capital Management in Spain with no rights issue. The issue price was based on the average market price of the period of 10 trading days prior to the corporate action. MOLOGEN's subscribed capital is now increased by 9 per cent to 8,056,131 Euro. The increase in share capital has been recorded at the register of companies.
Biotech Intelligence (http://www.biotech-intelligence.com/html/html/2096a7e7c8d52b0805b5f864eae0f230.html)